Skin & Subcutaneous Tissue

Diabetic foot ulcers: wound care and revascularization

Clinical Overview and When to Suspect Diabetic Foot Ulcer

— Lifetime risk in diabetes ~19–34%; recurrence ~40% within 1 year, ~65% within 5 years.

— Diabetic foot ulcers (DFU) precede ~85% of nontraumatic lower-extremity amputations.

— 5-year mortality after major amputation rivals many solid cancers (~50–70%).

— Long-standing diabetes (>10 y), poor glycemic control (A1c >8%), prior ulcer or amputation, ESRD on dialysis, smokers, vision impairment, foot deformity (Charcot, hammertoes, hallux valgus), inability to perform self-foot inspection.

— Sensorimotor neuropathy: loss of protective sensation → unnoticed trauma; intrinsic muscle wasting → claw toes, prominent metatarsal heads.

— Autonomic neuropathy: anhidrosis, dry/fissured skin, AV shunting → falsely warm but ischemic foot.

— PAD: tibial/peroneal small-vessel disease predominates; impairs healing and antibiotic delivery.

— Plantar metatarsal heads, great toe, heel → neuropathic, pressure-related.

— Tips of toes, lateral foot, dorsum → ischemic.

— Posterior heel → pressure ulcer in bedbound/hospitalized diabetics.

Definition: Full-thickness skin break distal to the malleoli in a patient with diabetes, typically arising from the triad of peripheral neuropathy, peripheral arterial disease (PAD), and repetitive mechanical trauma.

Epidemiology and stakes:

Who to suspect/screen aggressively:

Three driving pathophysiologies:

Classic ulcer locations as a clue to mechanism:

Step 3 management: Every diabetic patient deserves a comprehensive foot exam at least annually (USPSTF/ADA), and every visit if high-risk (prior ulcer, neuropathy, PAD, deformity). Document monofilament, pulses, and skin integrity — this is the single most tested ambulatory preventive intervention for DFU.

Board pearl: A painless ulcer over a callused plantar metatarsal head in a patient who "didn't notice it" is the prototypical neuropathic mal perforans ulcer — neuropathy, not infection or ischemia, is the root cause.

Presentation Patterns and Key History

— Neuropathic ulcer: painless, punched-out lesion under a callus at a pressure point (1st/5th MTP head, great toe); warm, dry foot with bounding pulses; patient often reports "noticed sock was wet/bloody."

— Ischemic ulcer: painful (unless concurrent neuropathy), dry necrotic base, located on toe tips, lateral 5th metatarsal, or heel; cool foot, absent pulses, dependent rubor with elevation pallor.

— Neuroischemic ulcer (most common, ~50%): mixed features; pain may be blunted, but tissue loss extends due to poor perfusion.

— Duration and trajectory of ulcer; any prior ulcers/amputations.

— Glycemic control (recent A1c), diabetes duration, insulin vs oral therapy.

— PAD symptoms: claudication, rest pain, prior revascularization; smoking pack-years.

— Footwear and activity: new shoes, barefoot walking, occupational standing.

— Constitutional/infection clues: fever, chills, drainage, malodor, worsening glucose control ("sugars off the wall" — a classic surrogate for occult infection).

— Comorbidities affecting healing: ESRD/dialysis, immunosuppression, malnutrition, heart failure, vision loss, depression, social support.

— Rapidly expanding cellulitis, gas, systemic toxicity → necrotizing infection until proven otherwise.

— Probe-to-bone sensation reported by patient or clinician → high likelihood of osteomyelitis.

— New foot deformity, warmth, swelling without ulcer in neuropathic patient → suspect acute Charcot neuroarthropathy, not cellulitis.

Three archetypal presentations — recognize on the stem:

Historical elements to extract every time:

Red flags on history:

Key distinction: Charcot foot is often misdiagnosed as cellulitis — both are warm and swollen, but Charcot is non-infected, neuropathic, and worsens with weight-bearing; elevation reduces warmth in Charcot but not infection. Missing this leads to inappropriate antibiotics and continued ambulation that destroys the midfoot.

Board pearl: Always ask "When did you last see your podiatrist/primary care for a foot exam?" — gaps in preventive care are a tested quality-of-care lever in Step 3 stems.

Physical Exam Findings and Hemodynamic Assessment

— Map ulcer location, size (length × width × depth), shape, base (granulation pink, slough yellow, eschar black), margins (undermined, rolled), exudate (serous, purulent, malodorous), surrounding erythema, induration, fluctuance.

— Look for callus, fissures, interdigital maceration, tinea pedis, onychomycosis — entry points for bacteria.

— Deformity: claw toes, hallux valgus, rocker-bottom midfoot (Charcot), prior amputation sites.

— 10-g Semmes-Weinstein monofilament at ≥4 plantar sites — failure to feel = loss of protective sensation.

— 128-Hz tuning fork at hallux (vibration).

— Pinprick, ankle reflexes.

— Ipswich touch test acceptable when monofilament unavailable.

— Palpate dorsalis pedis and posterior tibial pulses; auscultate femoral bruits.

— Skin: cool, shiny, hairless, dependent rubor, elevation pallor (Buerger sign) → ischemia.

— Capillary refill >3 sec supports PAD but nonspecific.

— >1.40: noncompressible (medial calcinosis, common in diabetes/CKD) → unreliable; get toe-brachial index (TBI).

— 0.90–1.40: normal.

— 0.70–0.89: mild PAD.

— 0.40–0.69: moderate PAD.

— <0.40: severe PAD/critical limb ischemia.

— TBI <0.70 = PAD; toe pressure <30 mm Hg or TcPO₂ <30 mm Hg = limb-threatening ischemia.

Inspection:

Neuropathy assessment (all 4 needed):

Vascular assessment:

Probe-to-bone (PTB) test: Sterile blunt probe touching bone at ulcer base → LR+ ~6 for osteomyelitis in high-prevalence settings; combine with imaging and ESR.

Hemodynamic measures — ankle-brachial index (ABI):

Step 3 management: Any DFU patient gets ABI + TBI at diagnosis. Falsely elevated ABI in a diabetic does not rule out PAD — get TBI or arterial duplex. This is one of the most testable "next best step" pivots.

Board pearl: Palpable pulses do not exclude microvascular disease severe enough to impair healing — pursue objective perfusion data when ulcer fails to progress.

Diagnostic Workup — Initial Labs, Imaging, and Wound Assessment

— Wagner: 0 (intact at-risk skin) → 5 (gangrene of entire foot).

— University of Texas: grades depth × stage (infection/ischemia) — better prognostic than Wagner.

— IDSA/IWGDF infection severity: uninfected, mild, moderate, severe (systemic SIRS).

— WIfI score (Wound, Ischemia, foot Infection) — predicts 1-year amputation risk and benefit of revascularization.

— CBC with diff (leukocytosis often blunted in diabetes), CMP (renal function for contrast, antibiotic dosing), glucose/A1c (control + healing surrogate), ESR and CRP (ESR >70 mm/hr raises osteomyelitis probability, LR+ ~11), blood cultures if systemic signs, lactate if sepsis concern, albumin/prealbumin (nutrition).

— Wound cultures: Obtain after debridement of necrotic tissue from the deep base, not superficial swab. Superficial swabs grow colonizers and mislead therapy.

— Plain foot X-ray of every moderate/severe DFU and any ulcer suspected of osteomyelitis: cortical erosion, periosteal reaction, lytic lesions, sequestrum; also detects soft tissue gas, foreign body, Charcot collapse.

— Findings of osteomyelitis lag clinical disease by 2 weeks — a negative film does not exclude it.

— Arterial duplex ultrasound for hemodynamics and segmental localization.

— Pulse volume recordings complement ABI when calcified vessels obscure pressures.

Bedside wound classification — use a validated system:

Laboratory workup:

Imaging — start with plain radiographs:

Vascular initial imaging:

CCS pearl: Initial CCS orders for a moderate DFU should bundle: CBC, BMP, A1c, ESR, CRP, blood cultures (if febrile), plain foot X-ray (3 views), deep wound culture after sharp debridement, ABI/TBI, and a wound care/vascular consult. Don't forget tetanus status.

Board pearl: A superficial wound swab is a wrong-answer trap. The right answer for culture is deep tissue or bone biopsy after debridement — this changes pathogen yield and antibiotic selection dramatically and is the cornerstone of stewardship in DFU.

Diagnostic Workup — Advanced and Confirmatory Studies

— MRI with and without contrast is the imaging gold standard: sensitivity ~90%, specificity ~80%; shows marrow edema, abscess, sinus tracts, and surgical planning anatomy.

— Use labeled WBC scan + SPECT/CT or 18F-FDG PET/CT when MRI is contraindicated (pacemaker, severe metal artifact).

— Bone biopsy with histopathology and culture = definitive diagnosis; obtain percutaneously through uninvolved skin when possible to avoid contamination, and ideally after antibiotic-free window of 2 weeks if patient is stable.

— CT angiography (CTA) of lower extremity runoff — fast, good infrapopliteal detail; requires iodinated contrast (caution in CKD).

— MR angiography (MRA) — avoid gadolinium if eGFR <30 (NSF risk with linear agents historically; newer macrocyclic agents safer but still cautious).

— Digital subtraction angiography (DSA) — gold standard, typically combined with intervention.

— TcPO₂ and skin perfusion pressure map regional perfusion and predict wound healing capacity.

— Mild infections: often gram-positive monomicrobial (S. aureus, Streptococcus).

— Chronic, prior-antibiotic, severe, or limb-threatening: polymicrobial with GNRs (Pseudomonas in macerated/water-exposed wounds) and anaerobes (ischemic, malodorous, deep).

— MRSA risk factors: prior MRSA, recent hospitalization, high local prevalence.

Osteomyelitis confirmation (the central diagnostic question in moderate/severe DFU):

Advanced perfusion testing when revascularization is considered:

Microbiology nuances:

Key distinction: Neuropathic Charcot vs osteomyelitis on MRI — both show bone marrow edema. Favoring osteomyelitis: adjacent skin ulcer, sinus tract, abscess, focal cortical erosion. Favoring Charcot: midfoot (tarsometatarsal) location, subchondral cysts, joint-centered changes, no overlying ulcer. When unclear, bone biopsy resolves the question.

Board pearl: The single best test to diagnose DFU-associated osteomyelitis when probe-to-bone is positive and X-ray is equivocal is MRI; the single best confirmatory test overall is bone biopsy with culture and histology.

Risk Stratification and First-Line Management Logic

— Wound (0–3), Ischemia (0–3 by ABI/TBI/TcPO₂), foot Infection (0–3 by IDSA) → composite predicts 1-year amputation risk and benefit from revascularization.

— 1. Offloading — total contact cast (gold standard for plantar neuropathic ulcers), removable cast walker rendered irremovable, felted foam, crutches/wheelchair. Without offloading, no ulcer heals.

— 2. Debridement — sharp surgical debridement of callus, slough, necrotic tissue at every visit; converts chronic to acute wound, reduces bacterial burden.

— 3. Infection control — culture-guided antibiotics for clinically infected ulcers only (do not treat colonization).

— 4. Revascularization — restore pulsatile inline flow when ischemia threatens healing (TcPO₂ <30, toe pressure <30, ABI <0.5 in nonhealing ulcer).

— 5. Wound environment — moist wound healing, appropriate dressings, treatment of edema and comorbid conditions (glycemia, nutrition, smoking cessation).

— Outpatient acceptable for: mild infection, reliable patient, no systemic toxicity, ABI adequate, ability to offload.

— Admit for: moderate-severe infection, systemic signs, critical limb ischemia, inability to offload or comply, failed outpatient therapy, need for urgent surgical debridement or revascularization.

— Inpatient: 140–180 mg/dL (avoid hypoglycemia).

— Outpatient: A1c <8% is reasonable in this population; aggressive tightening doesn't accelerate healing and risks hypoglycemia.

WIfI staging drives decision-making:

The "Five-Pillar" management framework (memorize for boards):

Outpatient vs inpatient decision:

Glycemic targets in active DFU:

Step 3 management: The highest-yield single intervention for a plantar neuropathic ulcer is offloading with a total contact cast. If a stem asks "next best step" for a clean, granulating neuropathic plantar ulcer, the answer is offloading — not antibiotics, not hyperbaric oxygen.

Board pearl: Hyperbaric oxygen is adjunctive only for selected Wagner ≥3 ischemic ulcers failing standard therapy; it is never the first-line answer.

Pharmacotherapy — Antibiotic Selection and Adjuncts

— Mild (superficial, ≤2 cm erythema, no systemic signs): Oral, gram-positive coverage. Cephalexin 500 mg QID, dicloxacillin 500 mg QID, or amoxicillin-clavulanate 875/125 BID. If MRSA risk: TMP-SMX DS BID or doxycycline 100 mg BID. Duration 1–2 weeks.

— Moderate (deeper, >2 cm erythema, lymphangitis, fascia/muscle, no SIRS): Oral or IV, broader. Amoxicillin-clavulanate, ampicillin-sulbactam, or ertapenem; add vancomycin/linezolid/daptomycin if MRSA risk. Duration 2–3 weeks (longer if osteomyelitis).

— Severe (systemic signs, SIRS/sepsis, critical limb ischemia, gas, necrosis): IV broad-spectrum with antipseudomonal coverage. Piperacillin-tazobactam + vancomycin, or carbapenem + vancomycin; add clindamycin if necrotizing or toxin concern. Source control trumps antibiotics. Duration 2–4 weeks post-debridement.

— No residual infected bone after resection: 2–5 days antibiotics (soft tissue course).

— Residual infected bone: 6 weeks of culture-directed therapy.

— Amputation through clean margins: soft tissue course (1–2 weeks).

— Tetanus toxoid if booster >5 years and contaminated wound.

— Statin and antiplatelet (aspirin or clopidogrel) for all DFU patients with PAD — secondary CV prevention.

— Cilostazol for claudication symptoms (contraindicated in HF).

— Topical growth factors (becaplermin) and bioengineered skin substitutes for refractory clean wounds.

Treat only clinically infected ulcers (≥2 of: erythema, warmth, swelling, tenderness, purulence, induration). Bacterial colonization is universal and does not warrant antibiotics.

Empiric regimens by IDSA severity (tailor to local antibiogram and prior cultures):

Pseudomonas-directed therapy indicated for chronically wet/macerated wounds, prior pseudomonal isolates, or failed narrower therapy — pip-tazo, cefepime, meropenem, or ciprofloxacin (oral step-down).

Osteomyelitis duration:

Adjunctive pharmacotherapy:

Board pearl: Fluoroquinolones cover Pseudomonas orally but carry tendon rupture, aortic aneurysm, QT, and dysglycemia risks — in diabetics they can precipitate severe hypo- or hyperglycemia; counsel and avoid as reflexive choice.

Key distinction: Antibiotics treat infection, not ischemia or pressure. A nonhealing but non-infected ulcer does not benefit from antibiotics and accumulates resistance.

Revascularization and Procedural Management

— Chronic limb-threatening ischemia (CLTI): rest pain, nonhealing ulcer >2 weeks, or gangrene with objective ischemia (ABI <0.4, toe pressure <30, TcPO₂ <30).

— DFU not progressing despite optimal wound care and evidence of inadequate perfusion.

— WIfI stage 3–4 with ischemia component.

— Endovascular (angioplasty ± stenting, atherectomy): first-line for most diabetic patients given infrapopliteal/tibial disease pattern, comorbidities, and shorter recovery. Lower upfront morbidity; may need reintervention.

— Open bypass (vein conduit preferred — great saphenous): durable for long-segment occlusions, good runoff target, longer life expectancy. BEST-CLI trial (2022): in patients with adequate saphenous vein, surgical bypass had lower major adverse limb events than endovascular for CLTI.

— Hybrid procedures combine both.

— Sharp surgical debridement at bedside or OR — removes nonviable tissue, biofilm, callus.

— Drainage of abscess/compartment — emergent in deep space infections.

— Minor amputations (toe, ray, transmetatarsal) for nonsalvageable tissue with viable proximal foot.

— Major amputation (BKA/AKA) when limb is unsalvageable, life-threatening infection, or revascularization not feasible.

— Negative pressure wound therapy (NPWT/wound VAC): for large, deep, post-debridement, or post-amputation wounds — accelerates granulation, reduces edema.

— Skin grafting and flap coverage after granulation bed established.

— Hyperbaric oxygen therapy (HBOT): consider for Wagner 3+ ischemic wounds with failed revascularization or no revascularization option; evidence modest.

Indications for revascularization:

Modalities:

Procedural debridement:

Adjunctive procedural therapies:

Step 3 management: In CLTI with a nonhealing DFU, revascularize first, then definitively close or amputate. Performing major debridement or flap closure on an unperfused foot leads to failure and limb loss — this sequencing is heavily tested.

CCS pearl: Order vascular surgery consult early (within 24–48 hours) for any DFU with abnormal ABI/TBI or nonhealing course; document shared decision-making about endovascular vs open approach.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of multilevel PAD, frailty, sarcopenia, cognitive impairment, vision loss, and polypharmacy — all impair self-care and wound healing.

— Functional status (ambulation, ability to self-inspect, social support) dictates realistic outcomes — a non-ambulatory dementia patient may not benefit from aggressive revascularization.

— Pain perception blunted by neuropathy + cognitive change → ulcers present later and larger.

— Falls risk increases with offloading devices; consider physical therapy and home safety eval.

— Goals of care discussion is appropriate for advanced disease, especially when considering major amputation vs palliative wound care.

— Dialysis patients have ~10× higher amputation risk; ulcers heal poorly even with revascularization.

— Contrast-induced nephropathy: minimize iodinated contrast; use CO₂ angiography or IVUS-guided intervention in CKD 4–5.

— Gadolinium: avoid in eGFR <30 with linear agents; macrocyclic agents lower risk but use only when essential.

— Antibiotic renal dosing: vancomycin (trough/AUC-based), pip-tazo (reduce frequency), cefepime (neurotoxicity in CKD — myoclonus, encephalopathy), levofloxacin/ciprofloxacin (reduce dose).

— Avoid nephrotoxins: aminoglycosides except when essential; NSAIDs.

— Calciphylaxis can mimic ischemic ulcer in dialysis patients — painful, retiform purpura/necrosis on calf; needs different management (sodium thiosulfate, lower calcium-phosphate product).

— Coagulopathy and hypoalbuminemia impair healing.

— Adjust clindamycin, metronidazole, tigecycline in cirrhosis; monitor for hepatotoxicity with TMP-SMX, oxacillin/nafcillin.

— Higher risk of spontaneous bacterial complications and altered drug binding (albumin).

Elderly patients:

Renal impairment (very common — diabetes is leading cause of ESRD):

Hepatic impairment:

Key distinction: In dialysis patients, a black, exquisitely painful, retiform necrotic plaque on the calf is calciphylaxis, not classic DFU — biopsy and serum chemistries (Ca, PO₄, PTH) clinch the diagnosis. Misdiagnosis as ischemia or infection delays correct therapy.

Board pearl: Cefepime neurotoxicity in renal failure is a classic Step 3 stem — encephalopathy or myoclonus in a CKD patient on cefepime for a DFU; the answer is dose-adjust or switch.

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Pregestational diabetes (T1DM/T2DM) carries increased risk; gestational diabetes rarely causes DFU during the pregnancy itself.

— Imaging: plain X-ray with shielding acceptable when needed; MRI without gadolinium preferred over CTA; avoid gadolinium except when essential.

— Antibiotic safety: penicillins, cephalosporins, clindamycin, azithromycin safe. Avoid tetracyclines (teeth/bone), fluoroquinolones (cartilage concern), TMP-SMX in 1st and 3rd trimesters (folate antagonism, kernicterus risk). Vancomycin acceptable.

— Tight glycemic control improves healing and fetal outcomes; coordinate with MFM.

— DFU is rare; consider in adolescents with long-standing T1DM and neuropathy, or in type 2 diabetes in obese teens with poor control.

— Look for non-diabetic mimics in children: hereditary sensory neuropathy (HSAN), spina bifida (insensate foot), epidermolysis bullosa.

— Same offloading and debridement principles; growth plate considerations limit fluoroquinolones and tetracyclines.

— Atypical organisms — fungi (Candida, molds), mycobacteria, Nocardia — consider when standard antibiotics fail or histology shows granulomas.

— Lower threshold for deep tissue biopsy with fungal/AFB cultures.

— Acute: warm, swollen, erythematous foot without ulcer in neuropathic patient; X-ray may be normal early.

— Treatment: immediate immobilization in total contact cast and non-weight-bearing for months; bisphosphonates are not standard. Bone scan/MRI confirms.

— Chronic: rocker-bottom deformity → high ulcer risk → custom orthotics.

— Compliance with offloading and follow-up is the limiting factor — engage social work, shelter-based wound clinics, irremovable cast walkers.

Pregnancy:

Pediatrics:

Immunocompromised (transplant, chemotherapy, HIV):

Charcot neuroarthropathy (a critical "subgroup" to recognize):

Homeless or socially vulnerable patients:

Step 3 management: A pregnant patient with a DFU and possible osteomyelitis should get MRI without gadolinium as the safest advanced imaging, and beta-lactam-based antibiotics as empiric therapy; coordinate care with MFM and endocrinology.

Board pearl: A warm, swollen, deformed foot without ulcer in a neuropathic diabetic is acute Charcot until proven otherwise — load-bearing on this foot causes irreversible midfoot collapse.

Complications and Adverse Outcomes

— Cellulitis and abscess — most common; may spread along fascial planes of the foot (medial, central, lateral compartments).

— Osteomyelitis — present in 20–60% of moderate/severe DFU; chronic, relapsing course.

— Septic arthritis of MTP or interphalangeal joints — joint destruction if delayed.

— Deep space infection / plantar abscess — surgical emergency; risk of compartment syndrome of the foot.

— Necrotizing fasciitis — pain out of proportion, crepitus, gas on X-ray, systemic toxicity; mortality 20–40%; demands emergent surgical debridement plus broad-spectrum antibiotics (pip-tazo + vancomycin + clindamycin for toxin suppression).

— Gas gangrene (clostridial myonecrosis) — bronze skin, hemorrhagic bullae, crepitus.

— Sepsis and septic shock — particularly in patients with blunted neuropathic pain who present late.

— Bacteremia and endocarditis — especially with S. aureus.

— Acute kidney injury from sepsis, contrast, nephrotoxic antibiotics.

— Hyperglycemic crises (DKA/HHS) triggered by infection.

— Minor amputation (toe/ray/TMA) — ~10–20% of DFU patients.

— Major amputation (BKA/AKA) — ~5–10%; carries 5-year mortality 50–70%, comparable to many cancers.

— Contralateral limb loss — ~50% within 2–5 years of first major amputation — emphasize aggressive contralateral foot protection.

— Ulcer recurrence — 40% at 1 year, 65% at 5 years.

— Reduced mobility, depression, social isolation, loss of employment.

— Mortality from associated CV disease — most DFU patients die of MI or stroke, not the foot.

Local complications:

Systemic complications:

Limb outcomes:

Long-term and recurrence:

Key distinction: Pain out of proportion, rapidly advancing erythema, hemorrhagic bullae, crepitus, or systemic toxicity = necrotizing infection. Do not wait for imaging — go to OR. CT may show gas but should not delay surgery.

Board pearl: A diabetic with DFU who presents with new MI is unsurprising — cardiovascular disease is the leading cause of death in DFU patients, which is why statin and antiplatelet therapy are core secondary prevention even if the "foot" is the chief complaint.

When to Escalate Care — ICU, Consults, and Inpatient Triage

— Moderate or severe infection (IDSA): deep tissue involvement, systemic signs, failure of outpatient therapy.

— Critical limb ischemia requiring urgent revascularization.

— Inability to offload, comply, or arrange close follow-up.

— Metabolic decompensation — DKA, HHS, severe hyperglycemia from infection.

— Need for IV antibiotics, surgical debridement, or imaging unavailable as outpatient.

— Sepsis/septic shock requiring vasopressors or organ support.

— Necrotizing soft tissue infection pre- or post-op.

— DKA/HHS with hemodynamic instability or altered mental status.

— Vascular surgery — for any ABI <0.9, TBI <0.7, or nonhealing ulcer >2 weeks; emergent for CLTI.

— Podiatry or foot/ankle orthopedics — for debridement, offloading, minor amputations, Charcot management.

— Infectious disease — for severe infection, MDR organisms, osteomyelitis requiring prolonged therapy, immunocompromised hosts.

— Endocrinology — for glycemic optimization, especially T1DM or insulin pump issues.

— Wound care nursing/clinic — central to dressing strategy and longitudinal care.

— Plastic surgery — flap coverage for large defects.

— Nephrology — CKD/dialysis coordination, contrast planning.

— Nutrition — albumin <3.0, weight loss, poor wound progress.

— Social work / case management — discharge planning, home health, DME.

— Physical therapy — gait training, offloading device fitting, post-amputation rehab.

— Behavioral health — depression screening (PHQ-9); 30%+ of DFU patients have depression.

Admit to hospital when:

Admit to ICU when:

Consults to order (CCS-style sequencing):

CCS pearl: Don't pile all consults on day 1 in low-acuity cases — but in moderate/severe DFU, vascular surgery and podiatry within 24 hours are nearly always correct. Sepsis bundle (lactate, blood cultures, broad-spectrum antibiotics within 1 hour, fluids, source control) takes precedence in unstable patients.

Step 3 management: A diabetic with foot ulcer, fever, hypotension, and a glucose of 600 needs the sepsis bundle + DKA/HHS protocol + emergent surgical evaluation — concurrent, not sequential. Failure to identify the foot as source on rounds is a classic patient-safety stem.

Key Differentials — Same-Category (Lower Extremity Ulcers)

— Location: medial malleolus / gaiter area; shallow, irregular, exudative.

— Background: edema, hemosiderin, lipodermatosclerosis, varicosities.

— Pulses: usually intact; ABI normal.

— Treatment: compression therapy (30–40 mm Hg) — the defining intervention. Compression is contraindicated if ABI <0.5.

— Location: toe tips, lateral foot, dorsum; punched-out, dry, pale base.

— Painful, cool foot, absent pulses, prolonged capillary refill.

— Treatment centers on revascularization; compression contraindicated.

— Pressure points, painless, surrounded by callus, deep with clean base if uninfected.

— Treatment: offloading and debridement are central.

— Bony prominences (heel, sacrum) in immobilized patients.

— Staging I–IV plus unstageable/deep tissue injury.

— Prevention: turning, pressure-redistributing surfaces, nutrition.

— Features of both; modify compression based on ABI.

— Palpable purpura, livedo, retiform necrosis; systemic features; biopsy shows leukocytoclastic vasculitis. Treat underlying disease.

— Painful violaceous ulcer with undermined borders, often on lower legs; pathergy (worsens with debridement). Associated with IBD, RA, hematologic disease. Treatment: immunosuppression (steroids, cyclosporine, biologics) — debridement worsens it, a classic trap.

— Dialysis patient, exquisitely painful retiform necrosis on calf/thigh; treat with sodium thiosulfate, normalize Ca-PO₄.

— Where: medial malleolus (venous), toe tips (arterial), pressure points (neuropathic), bony prominences (pressure).

— Pain: minimal (neuropathic, venous), severe (arterial, pyoderma, calciphylaxis, vasculitis).

— Pulses: present (venous, neuropathic), absent (arterial).

— Edge: shallow irregular (venous), punched-out (arterial, neuropathic), undermined violaceous (pyoderma).

Venous stasis ulcer:

Arterial (ischemic) ulcer:

Neuropathic ulcer (classic DFU):

Pressure ulcer:

Mixed venous-arterial ulcer:

Vasculitic ulcer:

Pyoderma gangrenosum:

Calciphylaxis:

Key distinction (high-yield ulcer matrix):

Board pearl: Debriding a pyoderma gangrenosum lesion mistaken for DFU worsens it (pathergy) — recognize undermined violaceous borders, ask about IBD/RA, and biopsy the edge before cutting.

Key Differentials — Other-Category Mimics

— May mimic acute Charcot; both warm/swollen. Cellulitis: fever, leukocytosis, sharp erythema margin, responds to elevation only modestly; Charcot: afebrile, deformity, X-ray changes.

— Unilateral leg swelling, warmth, tenderness; ulcer absent. D-dimer, duplex ultrasound clarify. Beware concurrent DVT in immobilized DFU patient.

— Monoarticular pain, effusion, restricted ROM, fever — arthrocentesis with WBC, crystals, Gram stain, culture.

— Sudden monoarticular pain, erythema (often 1st MTP — podagra). Crystal exam on aspirate. Can be confused with infected DFU; ulcer absence and crystal evidence differentiate.

— Sharply demarcated, raised, fiery red plaque; group A Strep; treat with penicillin/cephalexin.

— Pruritic, eczematous patches; misdiagnosed as cellulitis (so-called "pseudocellulitis"). Bilateral involvement is a clue against cellulitis.

— Interdigital maceration, scaling; topical antifungal + treat secondary infection.

— Squamous cell carcinoma arising in a chronic ulcer of >3 months — biopsy any non-healing or atypical wound at 6–12 weeks.

— Blue toe syndrome with intact pulses post-catheterization; livedo reticularis; eosinophilia. Look for proximal source.

— Pain syndromes without ulcer; warmth and color change.

Cellulitis without ulcer (in a neuropathic foot):

Deep vein thrombosis (DVT):

Septic arthritis of ankle or MTP:

Acute gout / pseudogout:

Erysipelas:

Contact or stasis dermatitis:

Tinea pedis with secondary bacterial infection:

Skin malignancy in chronic wound (Marjolin ulcer):

Embolic phenomena (cholesterol emboli, septic emboli, endocarditis):

Erythromelalgia, complex regional pain syndrome:

Key distinction: Bilateral, symmetric lower leg erythema is rarely cellulitis — think stasis dermatitis or lipodermatosclerosis. Unilateral, sharply demarcated, with systemic signs supports cellulitis. Overuse of antibiotics for "bilateral cellulitis" is a recurring patient-safety theme.

Board pearl: Any chronic non-healing ulcer (>3 months) requires biopsy to rule out Marjolin ulcer (SCC) — particularly if edges become raised, friable, or hyperkeratotic; this transformation is the most missed malignancy in chronic wound care.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— A1c target individualized — typically <8% in DFU patients; tighter only if achievable without hypoglycemia.

— Prefer agents with CV/renal benefit: GLP-1 agonists (semaglutide, liraglutide) and SGLT2 inhibitors (empagliflozin, dapagliflozin) when not contraindicated. Note: SGLT2i carry small risk of Fournier gangrene and DKA; do not initiate in active severe infection — hold during sepsis/DFU hospitalization, restart at discharge if appropriate.

— Continue metformin if eGFR ≥30; hold during acute illness/contrast.

— High-intensity statin (atorvastatin 40–80, rosuvastatin 20–40) for all DFU + PAD patients; LDL goal <70 mg/dL (<55 in very high risk per ACC).

— Antiplatelet: aspirin 81 mg or clopidogrel 75 mg daily.

— Rivaroxaban 2.5 mg BID + aspirin (COMPASS regimen) for selected PAD patients to reduce MALE/MACE — weigh bleeding risk.

— BP control to <130/80; ACEi/ARB preferred.

— Smoking cessation — most modifiable risk factor; offer counseling + pharmacotherapy (varenicline, bupropion, NRT).

— Daily foot self-inspection (or by caregiver/mirror); wash and dry between toes; moisturize except interdigital spaces.

— Therapeutic footwear: custom molded shoes/inserts — Medicare therapeutic shoe benefit covers one pair plus 3 inserts per year for qualifying diabetics.

— Never go barefoot; check shoes for foreign objects.

— Professional nail and callus care — avoid self-bathroom surgery.

— Annual comprehensive foot exam by PCP/podiatry; more frequent (every 1–3 months) in high-risk patients with prior ulcer.

Glycemic control:

Cardiovascular risk reduction (do not forget — most patients die of CV disease):

Foot-specific prevention bundle:

Vaccinations: influenza annually, pneumococcal per ACIP, COVID-19, Tdap (tetanus booster q10y, sooner with wound).

Step 3 management: Discharge a healed DFU patient on statin + antiplatelet + ACEi/ARB + optimized diabetes regimen + custom therapeutic shoes + scheduled podiatry follow-up within 1–4 weeks. Missing any element is a tested gap.

Board pearl: The single most effective preventive intervention for recurrence is prescription therapeutic footwear with custom insoles — heavily tested as the right answer for "what reduces recurrent ulceration."

Follow-Up, Monitoring, and Counseling

— Active ulcer: weekly to biweekly wound clinic visits with serial measurements (length × width × depth, photograph).

— Expectation: ≥50% area reduction at 4 weeks predicts healing by 12 weeks; failure to do so prompts reassessment (offloading adherence, perfusion, infection, biopsy).

— After healing: podiatry follow-up at 1–3 month intervals lifelong; annual ABI if PAD present.

— Post-revascularization: vascular surgery follow-up with duplex surveillance at 1, 3, 6, 12 months, then annually.

— A1c every 3 months until at goal, then every 6 months.

— Renal function and electrolytes every 6–12 months (more often on ACEi/ARB, SGLT2i, diuretics).

— Lipid panel annually.

— Microalbuminuria annually (diabetic nephropathy).

— Dilated eye exam annually (retinopathy).

— Depression screening (PHQ-9) annually.

— Smoking status every visit.

— Self-foot exam education — demonstrate and have patient teach back; provide handheld mirror for sole inspection.

— Warning signs to report immediately: new ulcer, redness, swelling, drainage, fever, foul odor, color change, unexplained rise in blood sugar.

— Smoking cessation at every visit (5 A's: Ask, Advise, Assess, Assist, Arrange).

— Footwear and activity instruction; gradual increase in walking once healed.

— Nutrition — adequate protein (1.2–1.5 g/kg/day in healing), vitamin C, zinc if deficient.

— Mental health — depression and diabetes distress impair self-care; refer when PHQ-9 ≥10.

— Post-amputation: prosthetic fitting, gait training, contralateral limb protection.

— Cardiovascular and pulmonary rehab as appropriate.

Follow-up cadence after a DFU:

Monitoring parameters:

Counseling pillars:

Rehabilitation:

Step 3 management: A patient with a healing DFU at week 4 with <50% area reduction needs reassessment of all five pillars — recheck offloading adherence (look for cast wear pattern), perfusion (repeat TBI), infection (cultures, MRI), nutrition, and consider biopsy for malignancy or atypical organisms. Don't just "continue current therapy."

Board pearl: The 4-week 50% rule is one of the most tested wound-care benchmarks — memorize it as the trigger for treatment escalation.

Ethical, Legal, and Patient Safety Considerations

— Discuss alternatives (revascularization, conservative wound care, palliative approach), expected functional outcome, prosthetic options, mortality risk (5-year ~50–70% for major amputation), and contralateral limb risk.

— Use decision aids and shared decision-making, especially for elective vs urgent settings.

— In cognitively impaired patients, identify legal surrogate; document capacity assessment. Emergent amputation for life-threatening sepsis may proceed under implied consent if surrogate unavailable.

— A patient with decision-making capacity may refuse amputation even when life-threatening. Reassess understanding of consequences, address depression and reversible factors, involve palliative care, and document carefully. Coercion is unethical.

— Elder or vulnerable adult neglect — a chronic untreated ulcer in a dependent adult may trigger Adult Protective Services reporting; know your state's requirements.

— Surgical site infections and amputation rates are publicly reported quality metrics; not a clinical decision driver but contextually relevant.

— Discharge from hospital with active wound is a high-error window: ensure clear written wound care instructions, dressing supplies, antibiotic completion plan, scheduled follow-up within 1 week, and verified transportation.

— Medication reconciliation — patients leave on new antibiotics, often with insulin changes; review hypoglycemia signs.

— Communicate with primary care via discharge summary within 48 hours.

— DFU outcomes are worse in Black, Hispanic, and Native American patients and in those with low socioeconomic status — partly driven by delayed revascularization referral. Be vigilant about equitable consultation patterns.

— Medicare therapeutic shoe benefit is underutilized — proactive prescription is good practice.

— Avoid bilateral lower extremity antibiotic treatment for "bilateral cellulitis" when stasis dermatitis is the likely diagnosis — antibiotic overuse harm.

— Hold metformin in sepsis or contrast administration; hold SGLT2i during severe infection (DKA, Fournier risk).

— Document offloading prescription — if a patient ambulates on an unprotected DFU, ulcer fails to heal; failure to prescribe/educate is a documentation gap.

Informed consent for amputation:

Refusal of amputation:

Mandatory and quality reporting:

Transitions of care (high-risk handoff):

Health equity and access:

Patient safety pearls (Step 3 favorites):

Step 3 management: When a capacitated patient refuses recommended major amputation for life-threatening foot sepsis, the right next step is palliative care consultation and continued maximal medical therapy, not legal compulsion — respect autonomy while ensuring informed understanding.

High-Yield Associations and Rapid-Fire Clinical Facts

Triad causing DFU: neuropathy + PAD + trauma.

Most predictive single physical finding for healing potential: perfusion (TcPO₂, toe pressure) — not pulse exam alone.

Falsely elevated ABI in diabetes/CKD due to medial calcinosis (Mönckeberg sclerosis) — use TBI.

Probe-to-bone positive + elevated ESR (>70): very high probability of osteomyelitis.

MRI is the imaging gold standard for osteomyelitis; bone biopsy with culture is the diagnostic gold standard.

Most common pathogens: S. aureus (including MRSA), Streptococcus; polymicrobial with anaerobes and Pseudomonas in deep/chronic wounds.

Empiric antibiotics by severity: mild = gram-positive oral; moderate = broad oral/IV; severe = IV antipseudomonal + MRSA coverage.

Osteomyelitis treatment duration: 6 weeks if residual infected bone; shorter post-resection.

Offloading gold standard: total contact cast for plantar neuropathic ulcers.

4-week 50% area reduction rule predicts 12-week healing.

Adjuncts: NPWT for deep/large wounds; HBOT for selected Wagner ≥3 ischemic; growth factors and skin substitutes for refractory clean wounds.

BEST-CLI (2022): surgical bypass with adequate saphenous vein superior to endovascular in CLTI for MALE.

Charcot foot: midfoot rocker-bottom deformity; total contact cast + non-weight-bearing.

Calciphylaxis in dialysis: painful retiform necrosis; sodium thiosulfate.

Marjolin ulcer: SCC in chronic wound — biopsy nonhealing wounds.

Recurrence rate: ~40% at 1 year; custom therapeutic footwear reduces it.

Top cause of death in DFU patients: cardiovascular disease — hence statin + antiplatelet.

Vaccines: influenza, pneumococcal, COVID-19, Tdap.

USPSTF/ADA: comprehensive foot exam at least annually; every visit if high risk.

Medicare therapeutic shoe benefit: 1 pair shoes + 3 inserts/year for qualifying diabetics.

Smoking cessation: single most modifiable PAD risk factor.

Avoid in DFU sepsis: SGLT2i (Fournier, DKA), metformin (lactic acidosis with contrast/sepsis), NSAIDs (renal).

Cefepime neurotoxicity in renal failure — myoclonus, encephalopathy.

Fluoroquinolone risks: tendon rupture, aortic aneurysm, QT, dysglycemia.

Pyoderma gangrenosum: do not debride — pathergy worsens lesion; treat with immunosuppression.

Board pearl: If a stem mentions "bounding pulses, warm dry foot, painless punched-out ulcer under callus on the great toe" — answer = offloading with total contact cast, not antibiotics.

Board Question Stem Patterns

— 58-year-old with T2DM × 15 years notices a "wet sock"; painless 2-cm ulcer with overlying callus at 1st MTP head; warm foot, palpable DP/PT pulses, monofilament absent at 6 sites; A1c 9.2.

— Best next step: debridement of callus + total contact cast offloading + annual labs and foot exam plan. Wrong answers: empiric antibiotics, HBO, broad imaging.

— Chronic plantar ulcer 8 weeks, exposed bone visible/probed; ESR 92, CRP elevated; X-ray equivocal.

— Best next step: MRI to evaluate for osteomyelitis; bone biopsy for definitive diagnosis and culture.

— Painful tip-of-toe ulcer, dry necrotic, cool foot, absent pulses, ABI 0.35.

— Best next step: urgent vascular surgery consult and angiography for revascularization; antibiotics and debridement secondary; major debridement before revascularization is wrong.

— Diabetic with ulcer, ABI 1.3, pulses palpable but ulcer not healing.

— Best next step: toe-brachial index or TcPO₂ — calcified vessels falsify ABI.

— Diabetic with foot pain out of proportion, hemorrhagic bullae, crepitus, hypotension.

— Best next step: emergent surgical debridement + broad-spectrum IV antibiotics (pip-tazo + vancomycin + clindamycin) + sepsis resuscitation. Imaging should not delay OR.

— Neuropathic patient with warm, swollen, deformed foot, no ulcer, afebrile, normal WBC.

— Diagnosis: acute Charcot neuroarthropathy; treat with total contact cast + non-weight-bearing.

— Patient with IBD, painful ulcer with violaceous undermined border, worsening after recent debridement.

— Best next step: biopsy edge and systemic corticosteroids; stop aggressive debridement.

— Recently healed DFU patient on metformin and lisinopril.

— Add: high-intensity statin, aspirin, custom therapeutic shoes, smoking cessation, podiatry follow-up.

— ESRD patient on cefepime for DFU develops myoclonus and confusion.

— Best next step: discontinue or dose-adjust cefepime.

— Capacitated patient refuses major amputation for septic foot.

— Best next step: confirm capacity, address reversible factors, palliative care consult, continue medical therapy, respect autonomy.

Stem 1 — The neuropathic plantar ulcer:

Stem 2 — Probe-to-bone osteomyelitis:

Stem 3 — Critical limb ischemia:

Stem 4 — Falsely normal ABI:

Stem 5 — Necrotizing infection:

Stem 6 — Charcot mimicking cellulitis:

Stem 7 — Pyoderma gangrenosum trap:

Stem 8 — Secondary prevention:

Stem 9 — Cefepime neurotoxicity:

Stem 10 — Refusing amputation:

CCS pearl: In a CCS case of moderate DFU with possible osteomyelitis, the high-scoring order pattern is: admit, IV access, CBC/BMP/ESR/CRP/A1c/blood cultures, X-ray foot, MRI foot, deep wound + bone biopsy with cultures, vascular surgery and podiatry consults, ABI/TBI, empiric IV antibiotics after cultures, glycemic control protocol, offloading, nutrition consult, then narrow antibiotics by culture and de-escalate.

One-Line Recap

— Diagnose mechanism first: monofilament for neuropathy, ABI + TBI for perfusion, probe-to-bone + ESR/CRP + X-ray + MRI for osteomyelitis, deep tissue or bone biopsy for culture (never superficial swab). WIfI score stratifies amputation risk and revascularization benefit.

— Treat by severity, not reflex: mild infection = oral gram-positive antibiotics; moderate = broader oral/IV; severe = IV antipseudomonal + MRSA coverage; antibiotics never replace offloading, debridement, or revascularization. Treat infection, not colonization. Osteomyelitis with residual bone = 6 weeks of culture-guided therapy.

— Revascularize before definitive closure in CLTI; BEST-CLI supports surgical bypass with adequate saphenous vein, while endovascular remains first-line for many comorbid patients. Vascular surgery consult within 24–48 hours for any non-healing ulcer or abnormal hemodynamics.

— Prevent the next ulcer and the next MI: annual comprehensive foot exam (more frequent if prior ulcer), custom therapeutic footwear (Medicare benefit), daily self-inspection, smoking cessation, A1c individualized (~<8%), high-intensity statin + antiplatelet + ACEi/ARB, GLP-1 or SGLT2i for CV/renal benefit (hold SGLT2i during active severe infection), depression screening, and lifelong podiatry follow-up.

One-liner: Diabetic foot ulcers are managed by simultaneously addressing the five pillars — offloading, debridement, infection control, revascularization when ischemic, and wound environment optimization — while aggressively pursuing cardiovascular secondary prevention and lifelong recurrence prevention with therapeutic footwear and structured follow-up.

Rapid recap bullets:

Final board pearl: The most tested single intervention in any DFU question — offloading; the most tested single missed diagnosis — acute Charcot; the most tested single preventive measure — custom therapeutic footwear; the most tested single cause of death — cardiovascular disease. Anchor on these four and most DFU stems resolve cleanly.